Supernus Pharmaceuticals Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 4.56, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Supernus Pharmaceuticals Inc in Mar 31 2026 quarter, has decreased to 80 days, compared to 82 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 120 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 961, from overall ranking in the fourth quarter 2025 at 1944.

What is Receivable Turnover Ratio?
What is Supernus Pharmaceuticals Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SUPN Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	25.09 %	32.18 %	17.77 %	-7.65 %	-1.42 %
Y / Y Revenue Change	38.63 %	21.48 %	9.34 %	-1.71 %	4.3 %
Receivable Turnover Ratio (TTM)	4.56	4.45	4.55	4.64	4.56
SUPN's Total Ranking	# 961	# 1944	# 854	# 2472	# 1919
Accounts Receivable average collection period days	80	82	80	79	80
Seq. Receivable Change	-2.99 %	9.66 %	21.6 %	-3.3 %	2.51 %
Seq. Revenue Change	-1.83 %	10.13 %	16.11 %	10.43 %	-13.97 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 35
Healthcare Sector	# 121
Overall Market	# 961

Receivable Turnover Ratio Statistics
High	Average	Low
9.44	5.15	2.77
(Sep. 30, 2014)		(Dec. 30, 2013)

SUPN Company Profile • Back to SUPN Efficiency Comparisons • Compare SUPN Receivables Turnover Ratio to its Competitors

Financial Statements
Supernus Pharmaceuticals Inc 's Accounts Receivable	$ 182 Millions	Visit SUPN's Balance sheet
Supernus Pharmaceuticals Inc 's Sales TTM	$ 777 Millions	Visit SUPN's Income Statement
Sources of SUPN's Revenues		Visit SUPN's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
SUPN's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
SUPN's Growth Rates	SUPN's Roa	SUPN's Inventory Turnover Ratio	SUPN's Dividend Comparisons
SUPN's Profitability Ratios	SUPN's Roi	SUPN's Asset Turnover Ratio	SUPN's Dividend Growth
SUPN's Valuation Ratios	SUPN's Roe	SUPN's Financial Strength Ratios	SUPN's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Option Care Health Inc	11.65	$ 5,666.577 Millions	$ 486.439 Millions
Ensysce Biosciences Inc	11.55	$ 4.708 Millions	$ 0.407 Millions
Crinetics Pharmaceuticals Inc	11.52	$ 18.069 Millions	$ 1.569 Millions
Icu Medical Inc	11.46	$ 2,156.379 Millions	$ 188.157 Millions
Nrc Health	11.42	$ 138.642 Millions	$ 12.138 Millions
Nuvation Bio Inc	11.41	$ 142.121 Millions	$ 12.454 Millions
Integrated Biopharma Inc	11.34	$ 47.241 Millions	$ 4.165 Millions
National Healthcare Corp	11.07	$ 1,525.905 Millions	$ 137.813 Millions
Vireo Growth Inc.	11.01	$ 350.469 Millions	$ 31.834 Millions
Bioaffinity Technologies Inc	10.79	$ 5.660 Millions	$ 0.525 Millions
Vivos Therapeutics Inc	10.73	$ 19.092 Millions	$ 1.779 Millions
Veracyte Inc	10.68	$ 516.183 Millions	$ 48.353 Millions
Immucell Corporation	10.51	$ 29.035 Millions	$ 2.762 Millions
Kestra Medical Technologies Ltd	10.51	$ 93.819 Millions	$ 8.925 Millions
Lifeloc Technologies Inc	10.41	$ 9.044 Millions	$ 0.869 Millions
Monte Rosa Therapeutics Inc	10.39	$ 42.953 Millions	$ 4.136 Millions
International Stem Cell Corporation	10.23	$ 9.286 Millions	$ 0.908 Millions
Pavmed Inc	10.19	$ 0.107 Millions	$ 0.011 Millions
Viemed Healthcare Inc	10.16	$ 286.565 Millions	$ 28.217 Millions
Addus Homecare Corp	10.14	$ 1,447.070 Millions	$ 142.667 Millions
Utah Medical Products Inc	10.13	$ 36.745 Millions	$ 3.629 Millions
Petvivo Holdings Inc	10.10	$ 0.821 Millions	$ 0.081 Millions
Irhythm Holdings Inc	10.00	$ 787.387 Millions	$ 78.720 Millions
C4 Therapeutics Inc	9.97	$ 34.861 Millions	$ 3.496 Millions
Biodesix Inc	9.94	$ 96.096 Millions	$ 9.665 Millions
Radnet Inc	9.87	$ 2,144.442 Millions	$ 217.223 Millions
Lensar Inc	9.87	$ 57.704 Millions	$ 5.847 Millions
X4 Pharmaceuticals Inc	9.69	$ 9.014 Millions	$ 0.931 Millions
Septerna Inc	9.64	$ 72.255 Millions	$ 7.499 Millions
Encompass Health Corporation	9.63	$ 6,066.400 Millions	$ 629.625 Millions

Date modified: 2026-08-30T14:48:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.